BioRestorative Therapies, Inc. (BRTX)

NASDAQ: BRTX · IEX Real-Time Price · USD
2.83
+0.37 (15.04%)
At close: Sep 28, 2022 4:00 PM
2.74
-0.09 (-3.18%)
After-hours: Sep 28, 2022 7:34 PM EDT
15.04%
Market Cap 10.72M
Revenue (ttm) 100,100
Net Income (ttm) -34.08M
Shares Out 3.79M
EPS (ttm) -17.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 128,265
Open 2.92
Previous Close 2.46
Day's Range 2.76 - 3.44
52-Week Range 2.46 - 24.00
Beta 69.89
Analysts Buy
Price Target 37.74 (+1,233.6%)
Earnings Date Aug 15, 2022

About BRTX

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase ... [Read more...]

Industry Biotechnology
Founded 1997
CEO Mark Weinreb
Employees 7
Stock Exchange NASDAQ
Ticker Symbol BRTX
Full Company Profile

Financial Performance

In 2021, BRTX's revenue was $46,000, a decrease of -40.26% compared to the previous year's $77,000. Losses were -$44.30 million, 293.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BRTX stock is "Buy." The 12-month stock price forecast is 37.74, which is an increase of 1,233.57% from the latest price.

Price Target
$37.74
(1,233.57% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today ...

14 hours ago - GlobeNewsWire

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

MELVILLE, NY., Sept. 27, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today ...

1 day ago - GlobeNewsWire

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company's Phase 2 Clinical Trial ...

MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today a...

3 months ago - GlobeNewsWire

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic...

-- First Site Will Enroll First Patient in the Clinical Study--  MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a cli...

3 months ago - GlobeNewsWire

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chron...

MELVILLE, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “ BioRestorative ”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem cell-ba...

4 months ago - GlobeNewsWire

BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lum...

MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, toda...

5 months ago - GlobeNewsWire

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production o...

MELVILLE, N.Y., March 10, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today...

6 months ago - GlobeNewsWire

BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program

Notice of Allowance Grants Protection for BioRestorative's Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease

7 months ago - GlobeNewsWire

BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell

MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today ...

7 months ago - GlobeNewsWire

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoSte...

Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds

7 months ago - GlobeNewsWire

BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Ma...

MELVILLE, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, ...

8 months ago - GlobeNewsWire

BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regula...

MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today ...

8 months ago - GlobeNewsWire

BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference

MELVILLE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today ...

8 months ago - GlobeNewsWire

BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Enc...

MELVILLE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today ...

8 months ago - GlobeNewsWire

BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat C...

MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, ...

9 months ago - GlobeNewsWire

BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show

MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, ...

9 months ago - GlobeNewsWire

BioRestorative Therapies, Inc. Releases Year-End Message

MELVILLE, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, ...

9 months ago - GlobeNewsWire

BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

MELVILLE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, ...

9 months ago - GlobeNewsWire

BioRestorative Therapies Enters into Letter of Intent with PRC Clinical

PRC Clinical to Provide Start-up CRO Services for BRTX-100 Phase 2 Clinical Trial

10 months ago - GlobeNewsWire

BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer

MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, today announced that...

10 months ago - GlobeNewsWire

BioRestorative Therapies Announces Closing of $23 Million Public Offering

MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced the cl...

10 months ago - GlobeNewsWire

BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “BRTX” November 5, 2021

10 months ago - GlobeNewsWire

BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program

MELVILLE, N.Y., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“ BioRestorative ” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today a...

1 year ago - GlobeNewsWire

BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program

Issued Patent Grants Protection for an Implantable Scaffold using Brown Adipose Derived Stem Cells and Methods of Use

1 year ago - GlobeNewsWire